Dov B Ballak

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3128463/publications.pdf

Version: 2024-02-01

20 papers 883

759233 12 h-index 17 g-index

20 all docs 20 docs citations

20 times ranked

1821 citing authors

#	Article	IF	CITATIONS
1	IL-1 family members in the pathogenesis and treatment of metabolic disease: Focus on adipose tissue inflammation and insulin resistance. Cytokine, 2015, 75, 280-290.	3.2	194
2	IL-37 protects against obesity-induced inflammation and insulin resistance. Nature Communications, 2014, 5, 4711.	12.8	186
3	Interleukin-37 suppresses the osteogenic responses of human aortic valve interstitial cells in vitro and alleviates valve lesions in mice. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 1631-1636.	7.1	91
4	Interleukin 37 reverses the metabolic cost of inflammation, increases oxidative respiration, and improves exercise tolerance. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 2313-2318.	7.1	87
5	PPAR-alpha dependent regulation of vanin-1 mediates hepatic lipid metabolism. Journal of Hepatology, 2014, 61, 366-372.	3.7	64
6	One week treatment with the IL-1 receptor antagonist anakinra leads to a sustained improvement in insulin sensitivity in insulin resistant patients with type 1 diabetes mellitus. Clinical Immunology, 2015, $160, 155-162.$	3.2	53
7	Interleukin-37 treatment of mice with metabolic syndrome improves insulin sensitivity and reduces pro-inflammatory cytokine production in adipose tissue. Journal of Biological Chemistry, 2018, 293, 14224-14236.	3.4	42
8	Genetic and pharmacological inhibition of vanin-1 activity in animal models of type 2 diabetes. Scientific Reports, 2016, 6, 21906.	3.3	37
9	TLR-3 is Present in Human Adipocytes, but Its Signalling is Not Required for Obesity-Induced Inflammation in Adipose Tissue In Vivo. PLoS ONE, 2015, 10, e0123152.	2.5	33
10	Activation of Proteinase 3 Contributes to Nonalcoholic Fatty Liver Disease and Insulin Resistance. Molecular Medicine, 2016, 22, 202-214.	4.4	29
11	Combined B- and T-cell deficiency does not protect against obesity-induced glucose intolerance and inflammation. Cytokine, 2013, 62, 96-103.	3.2	23
12	MAP3K8 (TPL2/COT) Affects Obesity-Induced Adipose Tissue Inflammation without Systemic Effects in Humans and in Mice. PLoS ONE, 2014, 9, e89615.	2.5	18
13	Increased Adipocyte Size, Macrophage Infiltration, and Adverse Local Adipokine Profile in Perirenal Fat in Cushing's Syndrome. Obesity, 2017, 25, 1369-1374.	3.0	10
14	Transgenic mice expressing human IL-32 develop adipokine profiles resembling those of obesity-induced metabolic changes. Cytokine, 2020, 125, 154793.	3.2	6
15	IL-37 Expression Reduces Lean Body Mass in Mice by Reducing Food Intake. International Journal of Molecular Sciences, 2018, 19, 2264.	4.1	5
16	Glucose Kinetics in the Collagen-Induced Arthritis Model: An All-in-One Model to Assess Both Efficacy and Metabolic Side Effects of Glucocorticoids. PLoS ONE, 2014, 9, e98684.	2.5	4
17	PS21 - 101. One week of treatment with an IL-1 receptor antagonist improves insulin sensitivity in patients with type 1 diabetes mellitus: results from a clinical trial. Nederlands Tijdschrift Voor Diabetologie, 2012, 10, 170-171.	0.0	1
18	PS2 - 9. Effect of B- and T-cell deficiency on obesity-induced inflammation and insulin resistance. Nederlands Tijdschrift Voor Diabetologie, 2011, 9, 96-96.	0.0	0

#	Article	lF	CITATIONS
19	PS21 - 102. IL-37 protects against obesity-induced inflammation and insulin resistance in mice. Nederlands Tijdschrift Voor Diabetologie, 2012, 10, 171-171.	0.0	O
20	PS1 - 1. TLR-3 is highly expressed in human adipocytes, but deficiency of TLR3 does not protect against obesity-induced inflammation and insulin resistance in mice. Nederlands Tijdschrift Voor Diabetologie, 2013, 11, 133-133.	0.0	0